Another single-center randomized phase 2 study of maintenance chemotherapy alone versus stereotactic ablative radiotherapy followed by maintenance chemotherapy for patients with limited metastatic NSCLC (primary plus up to five metastatic sites) with no EGFR-targetable or ALK-targetable mutations but who did achieve a partial response or stable disease after induction chemotherapy also obtained gratifying results (7). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.